Pharmacy Benefit Manager (PBM) execs testify before US Senate
April 10, 2019Research and Development PBMs, Rebates, Senate, US, pharma, senator, sfc
Executives representing pharmacy benefit managers (PBMs) appeared before the US Senate Finance Committee on Tuesday as they testified on the …
Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues
April 9, 2019Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma
The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
April 9, 2019Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …
FDA refuses to review Zogenix’s Fintepla in Dravet syndrome, shares tumble 30%
April 9, 2019Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix
California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to …
ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1
April 9, 2019Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …
Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer
April 8, 2019Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma
Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …
Kymab announces Merck exec Simon Sturge as new CEO
April 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma
UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …
Protecting public health: Is real-world evidence the key?
April 8, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence
In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …
NICE turns down Astellas’ Xtandi in prostate cancer
April 8, 2019Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer
Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …
Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership
April 8, 2019Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …
Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds
April 8, 2019Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data
A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …
€100m expansion of J&J’s Limerick manufacturing facility to bring up to 300 jobs
April 8, 2019Manufacturing and Production, Sales and Marketing
Johnson & Johnson has revealed plans to expand its existing Vision Care facilities at the National Technology Park in Limerick, …
Merrimack shuts down development of investigational cancer drug, staff cuts to follow
April 8, 2019Research and Development, Sales and Marketing cacner, merrimack, oncology, pharma
Merrimack Pharmaceuticals has taken the decision to terminate development of its antibody-directed nanotherapeutic cancer therapy MM-310 in the treatment of …
Top Ten most popular articles on Pharmafile.com this week!
April 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, Northern Ireland, Novartis, Placebo, UK, brexit, pharma
As Brexit looms, pharma trade lobby the ABPI called for a ban on exports of medicines in the case of …
FDA approves Pfizer’s Ibrance for advanced male breast cancer
April 5, 2019Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund
April 5, 2019Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo
NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …
Sacklers file motion to throw lawsuit out of court
April 5, 2019Medical Communications Massachusetts, OxyContin, Purdue Pharma, opioid crisis, opioids, sackler
Members of the Sackler family have asked a judge to throw a lawsuit – filed by Massachusetts attorney general Maura …
Memorial Sloan Kettering Cancer Center officials violated conflict of interest policies
April 5, 2019Medical Communications, Research and Development Cancer, Memorial Sloan Kettering Cancer Center, oncology, research
Top officials at the Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, according to details …
Crescendo Biologics selects current CFO Theodora Harold as new CEO
April 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Cambridge, Crescendo Biologics, Dr Peter Pack, Theo Harold, cfo
Cambridge, UK-based Crescendo Biologics have said current Chief Financial Officer (CFO) Theodora Harold will take over from Dr Peter Pack …
AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome
April 4, 2019Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma
AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
